rivaroxaban accord
accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotické činidla - prevence žilní tromboembolie (vte) u dospělých pacientů, kteří podstoupili elektivní operaci náhrady kyčelního nebo kolenního kloubu. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 for haemodynamically unstable pe patients. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 pro hemodynamicky nestabilní pe pacientů). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 a 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
aboxoma 2,5mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17381 apixaban - potahovaná tableta - 2,5mg - apixaban
aboxoma 5mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17381 apixaban - potahovaná tableta - 5mg - apixaban
anbinex 50iu/ml prášek a rozpouštědlo pro injekční roztok
instituto grifols, s.a., barcelona array - 4729 antitrombin iii - prášek a rozpouštědlo pro injekční roztok - 50iu/ml - antitrombin iii
antithrombin iii baxalta 50iu/ml prášek a rozpouštědlo pro infuzní roztok
baxalta innovations gmbh, vídeň array - 4729 antitrombin iii - prášek a rozpouštědlo pro infuzní roztok - 50iu/ml - antitrombin iii
apixaban viatris 2,5mg potahovaná tableta
viatris limited, dublin array - 17381 apixaban - potahovaná tableta - 2,5mg - apixaban
apixaban viatris 5mg potahovaná tableta
viatris limited, dublin array - 17381 apixaban - potahovaná tableta - 5mg - apixaban
apixaban sandoz 2,5mg potahovaná tableta
sandoz s.r.o., praha array - 17381 apixaban - potahovaná tableta - 2,5mg - apixaban
apixaban sandoz 5mg potahovaná tableta
sandoz s.r.o., praha array - 17381 apixaban - potahovaná tableta - 5mg - apixaban
apixaban stada 2,5mg potahovaná tableta
stada arzneimittel ag, bad vilbel array - 17381 apixaban - potahovaná tableta - 2,5mg - apixaban